Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Efficacy and safety of agomelatine (25 mg/day with potential blinded adjustment to 50 mg/day) for 12 weeks in non-depressed out-patients with Generalized Anxiety Disorder. A 12-week randomised, double-blind, placebo-controlled, with escitalopram (10 mg/day with potential blinded adjustment to 20 mg/day) as validator, 3-arm parallel groups, international multicenter study.

Next Previous
Trial Profile

Efficacy and safety of agomelatine (25 mg/day with potential blinded adjustment to 50 mg/day) for 12 weeks in non-depressed out-patients with Generalized Anxiety Disorder. A 12-week randomised, double-blind, placebo-controlled, with escitalopram (10 mg/day with potential blinded adjustment to 20 mg/day) as validator, 3-arm parallel groups, international multicenter study.

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 10 Oct 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Agomelatine (Primary) ; Escitalopram
  • Indications Generalised anxiety disorder
  • Focus Pharmacogenomic; Registrational; Therapeutic Use

Most Recent Events

  • 04 Feb 2021 Results of meta-analysis of 3 studies (EudraCT2004-002577-23; ISRCTN03554974; EudraCT2012-001666-15) assessing effects of agomelatine on anxious symptoms and functional impairment, published in the Advances in Therapy.
  • 07 Jun 2012 Results reported at the 28th International Congress of Cellegium Internationale Neuro-Psychopharmacologicum.
  • 18 Aug 2011 Additional trial locations identified as reported by ISRCTN: Current Controlled Trials.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top